Hemispherx Biopharma Inc (HEB)

1.26
0.02 1.60
AMEX : Health Care
Prev Close 1.24
Open 1.25
Day Low/High 1.24 / 1.29
52 Wk Low/High 0.06 / 0.21
Volume 61.46K
Avg Volume 166.20K
Exchange AMEX
Shares Outstanding 20.74M
Market Cap 27.17M
EPS -0.70
Div & Yield N.A. (N.A)

Latest News

Hemispherx Biopharma To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

Hemispherx Biopharma To Present At The 18th Annual Rodman & Renshaw Global Investment Conference

Recent Articles on Hemispherx Biopharma by BioWorld and Pink Sheet Posted to Corporate Website

Hemispherx Biopharma Enters Into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes With Insurance Carriers, And Obtaining Commitments Of $3.5 Million In Payments To Company

Hemispherx Biopharma Enters Into Settlement Agreements Dismissing All Pending Shareholder Derivative Litigation, Resolving Disputes With Insurance Carriers, And Obtaining Commitments Of $3.5 Million In Payments To Company

CEO Says Series of Coordinated Settlements Should Allow the New Management Team to Focus Exclusively on the Company's Long-Term Commercial, Research and Financial Objectives

Hemispherx Biopharma Renews Sales, Marketing, Distribution And Supply Agreement With GP Pharm

Hemispherx Biopharma Renews Sales, Marketing, Distribution And Supply Agreement With GP Pharm

Initial Target is ANMAT Approval to Treat Chronic Fatigue Syndrome Patients in Argentina

Insider Trading Alert - HEB, EPAY And STOR Traded By Insiders

Insider Trading Alert - HEB, EPAY And STOR Traded By Insiders

Stocks with insider trader activity include HEB, EPAY and STOR

Hemispherx Biopharma Reviews Ampligen® Data With National Institute Of Neurological Disorders And Stroke (NINDS)

Hemispherx Biopharma Reviews Ampligen® Data With National Institute Of Neurological Disorders And Stroke (NINDS)

National Institutes of Health Research Focus on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is Set to be a Game Changer for Patients